Minervax AB
559235-0085ActiveDeveloping a life-saving prophylactic vaccine against Group B Streptococcus.
Biotechnology Companyminervax.com
Oversikt
- 20–49
- Ansatte
- 50–100mill SEK
- Omsetning
- 2020
- Grunnlagt
Nøkkelbeslutningstakere
Per Fischer
CEO
@minervax.com
Bengt Johansson Lindbom
CSO
Christopher Gagliardi
Board member
Tal Zaks
Board member
+22 flere kontakter i Funnelfeedr
Beskrivelse
MinervaX is a clinical-stage biotechnology company dedicated to making a significant global impact through medical innovation. The organization focuses specifically on developing a state-of-the-art prophylactic vaccine targeting Group B Streptococcus (GBS). Their primary motivation is to prevent adv...